These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12192203)

  • 21. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?
    Lonardo A
    Dig Dis; 1999; 17(2):80-9. PubMed ID: 10545713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non alcoholic steatohepatitis: an emergent and potentially serious pathology].
    Elloumi H; Arfaoui D; Joudène M; Sriha B; Korbi M; Ajmi S
    Tunis Med; 2004 Jun; 82(6):484-91. PubMed ID: 15517946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-alcoholic steatohepatitis].
    Duvnjak M; Virović L
    Acta Med Croatica; 2003; 57(3):189-99. PubMed ID: 14582465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR; Torres DM; Harrison SA
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Obesity and non-alcoholic steatohepatitis].
    Méndez-Sánchez N; Chávez-Tapia NC; Uribe M
    Gac Med Mex; 2004; 140 Suppl 2():S67-72. PubMed ID: 15641474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.
    Medina J; Fernández-Salazar LI; García-Buey L; Moreno-Otero R
    Diabetes Care; 2004 Aug; 27(8):2057-66. PubMed ID: 15277442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
    Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
    Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic steatohepatitis.
    Sheth SG; Gordon FD; Chopra S
    Ann Intern Med; 1997 Jan; 126(2):137-45. PubMed ID: 9005748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Definition and management of non-alcoholic steatohepatitis (NASH)].
    Hütteroth TH
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S64-7. PubMed ID: 11450617
    [No Abstract]   [Full Text] [Related]  

  • 32. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic steatohepatitis.
    Jansen PL
    Neth J Med; 2004; 62(7):217-24. PubMed ID: 15554595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on nonalcoholic fatty liver disease.
    McCullough AJ
    J Clin Gastroenterol; 2002 Mar; 34(3):255-62. PubMed ID: 11873108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Neuschwander-Tetri BA
    Am J Med Sci; 2005 Dec; 330(6):326-35. PubMed ID: 16355018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alcoholic and non-alcoholic steatohepatitis].
    Dufour JF; Oneta CM
    Ther Umsch; 2004 Aug; 61(8):505-12. PubMed ID: 15457967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease.
    Yu AS; Keeffe EB
    Rev Gastroenterol Disord; 2002; 2(1):11-9. PubMed ID: 12122975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
    Anderson N; Borlak J
    Pharmacol Rev; 2008 Sep; 60(3):311-57. PubMed ID: 18922966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.